Resolutions at the Annual General Meeting in Biotage AB on April 26, 2007

Resolutions at the Annual General Meeting in Biotage AB on April 26, 2007

At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April
26, 2007, the following resolutions were passed, among others.

Appropriation of the company's result
The General Meeting resolved that the company's accumulated losses shall be
carried forward.

Board of Directors etc.
The General Meeting resolved to re-elect Ove Mattsson, Thomas Eklund, Annika
Espander, Staffan Lindstrand, Anders Rydin, Bengt Samuelsson and Mathias Uhlén
as Board members and to elect Axel Broms and Per-Olof Eriksson as new Board
members. The General Meeting resolved to appoint Ove Mattsson Chairman of the
Board. The former Board members Jeff Bork and Björn Odlander had expressed their
wish to resign as Board members.

The General Meeting resolved that a fee of SEK 1,400,000 shall be paid to the
Board of Directors for the period up to and including the Annual General Meeting
2008 to be distributed as follows: the Chairman shall receive SEK 400,000 and
each of the other Board members elected by the General Meeting who are not
employed by the company shall receive SEK 125,000. In addition to that, a fee
shall be paid to the members of the Auditing Committee of an aggregate of not
more than SEK 100,000, whereof the Chairman shall receive SEK 50,000 and the
other members SEK 25,000 each.

At the General Meeting it was informed that the employee organisation
“Civilingenjörsförbundet” and “Naturvetarna” at Biotage have appointed
Per-Gunnar Eriksson to employee Board representative, and that the employee
organisation “SIF” at Biotage has appointed Maritha Lundin to alternate Board
representative. 

Nomination Committee
The General Meeting resolved that the Chairman of the Board of Directors shall
be appointed as member of the Nomination Committee and shall be instructed to
appoint, in consultation with the (by voting rights) major shareholders of the
company as per September 1, 2007, another three members. The names of such
members shall be published no later than six months before the Annual General
Meeting 2008. The Nomination Committee shall appoint one of the members to be
the Chairman of the Committee. The Chairman of the Board may not be appointed
Chairman of the Nomination Committee.

The Nomination Committee shall, before the Annual General Meeting 2008, prepare
proposals for the election of Chairman and other members of the Board of
Directors, the election of auditors, the election of Chairman of the Annual
General Meeting, the determination of fees and matters pertaining thereto.

Resolution on guidelines for compensation for the executive management
The General Meeting resolved to adopt guidelines for compensation for the
executive management in accordance with the proposal by the Board of Directors.

Authorization for the Board of Directors to issue shares and/or convertibles
The General Meeting resolved to authorize the Board to issue shares and/or
convertibles with or without deviation from the shareholders' pre-emption
rights. The Board of Directors shall have the right to resolve that the shares
and/or the convertibles shall be paid in kind or otherwise be subject to
conditions referred to in Chapter 2 Section 5 second paragraph 1-3 and 5 of the
Swedish Companies Act or that the shares and/or the convertibles shall be
subscribed for with a right of set-off. The Board's resolutions may result in an
increase of the number of shares in the company by not more than 8,800,000
shares in total. 

Adoption of a global employee stock option program and authorization for the
Board of Directors to issue warrants with the right to subscribe for new shares
in relation to the employee stock option program
The General Meeting resolved to adopt a global employee stock option program,
according to which employees of the group can be allocated, at no premium, in
total not more than 1,000,000 employee stock options until the Annual General
Meeting 2008.

The exercise price for the options shall correspond to the higher of either (a)
110 per cent of the average of the last price paid for a share in Biotage as
quoted on the Official List of the Stockholm Stock Exchange during the five
trading days immediately preceding the date of allocation, and (b) 110 per cent
of the last price paid on the date of allocation. The duration period shall be
seven years from the date of allocation and the options vest after one to three
years after the date of allocation, by one-third of the number of allocated
options for each one-year period.

Upon full exercise of all the employee stock options, the employees will acquire
shares in the company corresponding to approximately 1.1 per cent of the share
capital and votes based on the existing number of shares (after such exercise).

In order to secure the proposed employee stock option program, the General
Meeting resolved to authorize the Board to issue warrants with the right to
subscribe for new shares in Biotage. In total, not more than 1,250,000 warrants
may be issued, of which a total of not more than 250,000 warrants are intended
to be used in order to cover the costs that may arise because of the employee
stock option program. Each warrant shall entitle to subscription for one new
share in Biotage. The right to subscribe for the warrants shall, with deviation
from the shareholders' pre-emption rights, only vest with a bank, securities
broker or similar, alternatively a wholly owned subsidiary to the company,
appointed by the Board of Directors. 

Assuming that all warrants are exercised for subscription of new shares, the
company's share capital will increase by SEK 1,250,000, which corresponds to a
dilution of approximately 1.4 per cent of the share capital and votes based on
the existing number of shares (after such exercise).



Uppsala, April 26, 2007
Biotage AB (publ)
The Board of Directors

Contact:									
Torben Jörgensen, President and CEO						 
Tel: +46 707 490 584, torben.jorgensen@eu.biotage.com

About Biotage 
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of genetic
analysis and medicinal chemistry. In 2005 operations and products were acquired
from the American company Argonaut, further strengthening the medicinal
chemistry product range. The customers include the worlds top 30 pharmaceutical
companies, the worlds top 20 biotech companies, and leading academic institutes.
The company is headquartered in Uppsala and has offices in the U.S., Japan, UK,
Germany and several other European countries. Biotage has 332 employees and had
sales of 520 MSEK in 2006. Biotage is listed on the Stockholm stock exchange.
Website: www.biotage.com